NCT05922696

Cholecalciferol Supplementation in Hemodialysis Patients

Impact of Cholecalciferol Supplementation in Hemodialysis Patients

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Ain Shams University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is prospective single-blind randomized study, in Ain Shams University hospital) in Egypt, to assess the impact of Cholecalciferol on Anemia status in regular hemodialysis outpatients

Detailed description

This Srudy is to assess the Impact of Cholecalciferol on Anemia status in regular hemodialysis outpatients in terms of increase of Hgb \>11 g/dl, transferrin saturation (TSAT) of ≥ 30%, and ferritin levels to achieve a range of (300 to \< 800 ng/ml), and effect on Epoetin Dose needed. This study is also to adress the factors affecting the correcetion of Anemia by Cholecalciferol supplementation, such as oxidative stress and Inflammatory markers.

Conditions

• Anemia
• Hemodialysis Complication
• Vitamin D Deficiency

Interventions

Type	Name	Description
DRUG	Cholecalciferol	50.000IU weekly in Group A , or 200.000IU monthly in Group B

Timeline

• Start date: 2022-05-15
• Primary completion: 2022-09-15
• Completion: 2023-01-26
• First posted: 2023-06-28
• Last updated: 2023-06-28

Locations

1 site across 1 country: Egypt